First Tracks Biotherapeutics CFO files Form 3

First Tracks Biotherapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Ajim Tamboli.

Accepted by SEC EDGAR 04/23/2026 - 06:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

First Tracks Biotherapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Ajim Tamboli. A Form 3 is used to disclose an insider’s starting ownership when they first become a reporting person. In this filing data, no transactions or specific share holdings are listed.

Key Figures

Buy transactions: 0 shares Sell transactions: 0 shares Option exercises: 0 shares

3 metrics

Buy transactions 0 shares Form 3 transaction summary buyShares

Sell transactions 0 shares Form 3 transaction summary sellShares

Option exercises 0 shares Form 3 transaction summary exerciseShares

Key Terms

Form 3, reportingPersons, transactionSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Tamboli Ajim""

transactionSummary regulatory

""transactionSummary": { "buyCount": 0, "sellCount": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the TRAXV Form 3 filing for Ajim Tamboli show?

The Form 3 for TRAXV lists Ajim Tamboli as Chief Financial Officer and a reporting insider. The available data show no reported transactions or specific share holdings, serving mainly as an initial ownership reporting record.

Who is the reporting person in First Tracks Biotherapeutics’ Form 3?

The reporting person is Ajim Tamboli, Chief Financial Officer of First Tracks Biotherapeutics, Inc. This establishes him as an insider whose future trades in company securities will be reported on Forms 4 or 5, subject to SEC rules.

Does the TRAXV Form 3 disclose any insider stock transactions?

No insider stock transactions appear in the provided Form 3 data for TRAXV. The transaction summary shows zero buys, zero sells, and no derivative exercises, indicating this filing functions solely as an initial ownership statement.

What is the purpose of a Form 3 for First Tracks Biotherapeutics?

Form 3 is an SEC document that records an insider’s initial beneficial ownership in a company like First Tracks Biotherapeutics. It starts the public record for future insider trading disclosures, which are later reported on Forms 4 and 5 if transactions occur.

Are any derivative securities reported in Ajim Tamboli’s Form 3?

No derivative securities are reported in the available Form 3 data for Ajim Tamboli. The derivative summary section is empty, and exercise-related counts are zero, indicating no listed options, warrants, or similar instruments in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tamboli Ajim

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/17/2026

3. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Ajim Tamboli	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)